ArticleAmerican journal of translational research2026
A PDCA cycle-based early intensive lipid-lowering strategy improves LDL-C goal achievement and clinical outcomes after PCI in acute coronary syndrome patients.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate whether a PDCA cycle-based early intensive lipid-lowering strategy could improve LDL-C goal attainment in patients with acute coronary syndrome undergoing PCI.
methodsThis retrospective, single-center cohort study enrolled 203 consecutive ACS patients undergoing PCI between January 2022 and January 2025. Patients were assigned to a control group receiving standard lipid-lowering therapy (n=101) or a PDCA intervention group (n=102) managed through a Plan-Do-Check-Act cycle-based early intensive lipid-lowering protocol. The primary endpoint was LDL-C goal attainment at 12 weeks (<1.8 mmol/L or ≥50% reduction). Secondary endpoints included lipid dynamics, medication adherence, therapy intensification, safety outcomes, and lifestyle adherence. Laboratory, echocardiographic, and behavioral data were prospectively collected and analyzed by blinded investigators using standardized protocols.
resultsThe PDCA cycle-based strategy achieved greater and earlier reductions in LDL-C and total cholesterol, leading to higher LDL-C goal attainment (<1.8 mmol/L: 57.8% vs. 31.7%; ≥50% reduction: 61.7% vs. 28.7%; both P<0.001). High-intensity statin, ezetimibe, and PCSK9 inhibitor use were significantly higher, accompanied by improved medication adherence (94.38 ± 10.64% vs. 83.63 ± 11.56%, P<0.001) and lifestyle compliance. PDCA management enhanced LVEF improvement (from 53.84 ± 6.71 to 62.00 ± 6.09% vs. 52.91 ± 5.59 to 53.65 ± 6.09%; P<0.001) without increasing adverse events. Multivariate analysis confirmed PDCA intervention as an independent predictor of LDL-C goal achievement (OR 9.353, 95% CI 4.424-19.775; P<0.001).
conclusionA PDCA cycle-based early intensive lipid-lowering strategy significantly improved LDL-C goal achievement, medication and lifestyle adherence, and cardiac function after PCI in ACS patients, without increasing adverse events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.